Avalo to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Garry A. Neil will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022. The presentation will be pre-recorded and available on September 12 at 7:00 AM ET, accessible via the Investors section of the company's website. Avalo is a clinical-stage biotechnology firm focused on therapies targeting immune dysregulation by developing solutions that interact with the LIGHT-signaling network, which plays a role in autoimmune and inflammatory disorders.

WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.

The pre-recorded formal presentation will be made available on Monday, September 12, 2022 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the “News/Events” page in the Investors section of the Company’s website, www.avalotx.com.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor, form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT can moderate immune dysregulation in many acute and chronic inflammatory disorders.

For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo’s management but are subject to significant risks and uncertainties, including: Avalo's cash position and the potential need for it to raise additional capital; drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management and Board changes; regulatory risks; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo’s filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
csullivan@avalotx.com
410-803-6793

or

Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
339-970-2843

FAQ

When will Avalo Therapeutics' CEO present at the H.C. Wainwright Global Investment Conference?

Garry A. Neil, CEO of Avalo Therapeutics, will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022.

How can I access the presentation by Avalo Therapeutics at the conference?

The pre-recorded presentation will be available on September 12, 2022, at 7:00 AM ET on the Investors section of Avalo Therapeutics' website.

What is Avalo Therapeutics focusing on in their research?

Avalo Therapeutics is focusing on developing therapies that target the LIGHT-signaling network to treat immune dysregulation, particularly in autoimmune and inflammatory diseases.

What is the significance of the LIGHT-signaling network in Avalo Therapeutics' research?

The LIGHT-signaling network is crucial as its dysregulation is linked to autoimmune and inflammatory conditions, and Avalo aims to reduce LIGHT to mitigate these issues.

What stock symbol is associated with Avalo Therapeutics?

Avalo Therapeutics is traded under the stock symbol AVTX on Nasdaq.